Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00540072 | Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae | PHASE3 | COMPLETED | - | — | — | Jul 30, 2001 | Feb 27, 2002 | Nov 14, 2019 | - | — |
| NCT00538694 | Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia | PHASE3 | COMPLETED | - | — | — | Oct 31, 2000 | Sep 30, 2001 | Nov 14, 2019 | - | — |
| Name | Type | Description |
|---|---|---|
| daptomycin | DRUG | - |
Inclusion Criteria: 1. Provide signed and dated informed consent. 2. Adults, 18 years of age or older of either gender and of any race weighing up to 150 kg. Female patients of childbearing potential MUST be nonpregnant (confirmed by negative serum pregnancy test), nonlactating, and must be willing...